asthma
tradit
defin
clinic
ground
respiratori
diseas
character
recurr
revers
airway
obstruct
wheez
cough
dyspnea
recent
year
understand
asthma
expand
special
impact
airway
inflamm
sever
case
airway
remodel
pathogenesi
led
new
definit
describ
asthma
chronic
inflammatori
process
number
cell
cellular
event
involv
review
yang
repeat
measur
gener
index
airway
resist
pef
measur
larg
airway
resist
account
total
resist
gain
global
consensu
guid
therapeut
intervent
patient
year
age
bronchial
hyperreact
defin
decreas
mgml
methacholin
challeng
increas
administr
albuterol
salbutamol
patient
baselin
airflow
obstruct
methacholin
challeng
perform
patient
asthma
also
exhibit
elev
level
fraction
exhal
nitric
oxid
util
marker
airway
inflamm
measur
fraction
exhal
nitric
oxid
shown
enhanc
diagnosi
asthma
detect
deterior
control
asthma
monitor
respons
antiinflammatori
therapi
level
decreas
inhal
corticosteroid
treatment
especi
individu
asthma
atopi
measur
fraction
exhal
nitric
oxid
may
becom
import
tool
clinic
practic
furthermor
increas
sputumassoci
immun
cell
particular
eosinophil
count
taken
account
diagnosi
sinc
believ
reflect
underli
airway
inflamm
eosinophil
count
also
use
predict
asthma
control
discontinu
inhal
corticosteroid
particularli
infant
young
children
import
differenti
diagnos
exclud
recurr
wheez
attribut
bronchial
hyperreact
asthma
children
receiv
full
set
vaccin
first
year
life
whoop
cough
alway
exclud
droplet
precaut
implement
long
result
b
ordetella
pertussi
diagnost
pend
aspir
foreign
bodi
may
caus
recurr
episod
pulmonari
infect
make
reason
confirm
clinic
diagnosi
pneumonia
chest
xray
hospit
children
also
control
complet
resolut
pulmonari
infiltr
week
cystic
fibrosi
also
exclud
sweat
test
child
sever
recurr
respiratori
tract
infect
medic
histori
patient
may
reveal
prematur
prolong
ventil
supplement
oxygen
therapi
subsequ
bronchopulmonari
dysplasia
gastroesophag
reflux
diseas
nocturn
attack
wheez
cough
may
trigger
recurr
wheez
respiratori
infect
due
microaspir
sinus
caus
posterior
drainageassoci
chronic
cough
consid
school
age
children
asthma
symptom
chronic
persist
infect
airway
atyp
bacteria
mycoplasma
spp
chlamydophila
spp
may
caus
recurr
wheez
episod
beyond
simpl
acut
exacerb
recent
line
evid
suggest
infect
atyp
bacteria
may
play
addit
role
pathogenesi
asthma
result
continu
research
number
potenti
risk
factor
eg
tobacco
smoke
hous
dust
mite
mould
pet
cockroach
allergen
genet
background
atopi
develop
asthma
increas
review
arruda
et
al
breastfeed
altern
use
document
hypoallergen
formula
least
month
seem
protect
effect
may
explain
observ
matern
intak
probiot
lactobacillu
rhamnosu
gg
late
pregnanc
follow
administr
l
rhamnosu
gg
infant
first
month
life
significantli
decreas
proport
children
atop
eczema
verum
group
thu
gut
microflora
might
hitherto
unexplor
sourc
natur
immunomodul
probiot
prevent
atop
diseas
howev
protect
effect
frequent
earli
exposur
potenti
pathogen
infect
preval
asthma
question
studi
therebi
one
prospect
trial
foster
hypothesi
antibacteri
treatment
infanc
relat
higher
risk
asthma
later
life
nevertheless
mani
wheez
episod
infant
trigger
viral
infect
treat
antibacteri
although
risk
bacteri
superinfect
gener
influenza
exclud
misus
antibacteri
may
bias
studi
evalu
antibacteri
treatment
earli
infanc
risk
factor
subsequ
asthma
howev
note
contrast
misus
sophist
use
antibacteri
particular
macrolid
may
downregul
prolong
inflamm
increas
mucu
clearanc
prevent
biofilm
format
also
decreas
bacteri
virul
review
shinkai
rubin
diagnost
viral
respiratori
tract
infect
reli
differ
method
gener
depend
skill
experi
virolog
laboratori
fortun
virus
caus
respiratori
infect
cultiv
permiss
cell
cultur
provid
necessari
equip
technolog
avail
howev
cultur
method
sometim
timeconsum
virus
may
extrem
difficult
recov
eg
case
hmpv
rapid
diagnost
method
like
revers
transcriptas
polymeras
chain
reaction
rtpcr
antigen
detect
assay
prefer
clinic
practic
antigen
detect
enzymelink
immunosorb
assay
elisa
method
avail
rsv
iv
piv
adv
provid
posit
neg
result
minut
hour
howev
assay
develop
routin
use
newli
detect
pathogen
like
hmpv
hcov
method
choic
detect
viral
nucleic
acid
thu
pcr
rtpcr
play
crucial
role
detect
newli
detect
viral
respiratori
pathogen
agent
howev
still
unknown
long
pcr
remain
posit
respiratori
specimen
cessat
clinic
ill
besid
high
sensit
rtpcrpcr
method
advantag
detect
addit
infect
anoth
viru
commonli
describ
coinfect
howev
viral
rna
may
take
week
disappear
nasal
mucu
eg
onset
symptomat
respiratori
infect
rhinovirus
may
clear
virus
detect
respons
clinic
symptom
therefor
durat
detect
investig
avoid
fals
posit
pcr
result
week
possibl
month
first
infect
seri
detail
investig
clinic
laboratori
radiolog
present
communityacquir
pneumonia
children
age
year
reveal
combin
clinic
sign
host
acut
phase
respons
marker
cutoff
valu
radiolog
find
reliabl
differenti
bacteri
viral
atyp
typic
pneumonia
age
group
thu
microbiolog
diagnost
effort
indispens
identifi
respons
respiratori
pathogen
initi
c
pneumonia
design
twar
strain
c
psittaci
differ
dna
sequenc
epidemiolog
also
pathogen
led
actual
classif
pathogen
furthermor
high
preval
igg
antibodi
c
pneumonia
gener
popul
adult
thu
laboratori
diagnosi
gener
base
serolog
test
result
consensu
confer
held
center
diseas
control
prevent
usa
dowel
colleagu
conclud
acut
infect
c
pneumonia
accompani
appear
igm
antibodi
detect
week
onset
clinic
symptom
thereaft
igm
antibodi
detect
month
replac
low
titer
igg
antibodi
firstli
appear
week
infect
dowel
colleagu
conclud
use
singl
paramet
lead
complet
diagnosi
pcr
although
yet
standard
increas
import
futur
tool
diagnosi
furthermor
state
wholli
satisfactori
serolog
method
diagnosi
c
pneumonia
infect
pcr
method
pathogen
detect
increas
import
second
atyp
bacteri
pathogen
relat
asthma
pneumonia
howev
major
obstacl
use
pcr
singl
method
detect
pneumonia
c
pneumonia
distinguish
viabl
nonviabl
bacteria
exampl
antibacteri
chemotherapi
thu
least
one
method
recommend
laboratori
diagnosi
infect
frequent
use
method
detect
specif
antibodi
major
studi
investig
associ
asthma
c
pneumonia
infect
microimmunofluoresc
test
altern
serolog
assay
describ
lack
commerci
avail
limit
specif
crossreact
antibodi
imped
broader
use
practic
laboratori
diagnosi
pneumonia
complex
even
difficult
although
pneumonia
cultiv
solid
media
growth
extrem
slow
day
cultur
method
extrem
insensit
thu
difficult
get
rapid
diagnost
result
method
howev
pneumonia
isol
swab
retronas
aspir
sputum
bal
case
subsequ
cultur
pathogen
requir
desir
specimen
solv
ie
materi
mix
medium
adequ
transport
media
rapid
detect
materi
investig
enzym
immunoassay
oligonucleotid
hybrid
method
pcr
assay
cultur
solidphas
media
middles
granul
coloni
without
typic
fri
egg
appear
form
orient
pneumonia
identifi
via
glucos
cleavag
reaction
hemadsorpt
hemolysi
final
identif
procedur
finish
growth
inhibit
test
andor
epifluoresc
insensit
cultur
method
difficulti
method
addit
direct
indirect
detect
pneumonia
serolog
test
perform
tradit
serolog
detect
pneumonia
infect
perform
complement
fixat
assay
gener
limit
imposs
differenti
antibodi
subclass
ii
lack
specif
thu
iii
differenti
acut
chronic
previou
infect
meanwhil
commonli
use
serolog
test
replac
complement
fixat
elisa
method
major
advantag
assay
commerci
avail
test
specif
differenti
differ
stage
infect
diagnosi
atyp
respiratori
tract
infect
still
labori
sophist
expens
time
consum
urgent
need
sensit
specif
standard
econom
inexpens
diagnost
test
use
bedsid
least
yield
result
within
hour
pathogen
easili
identifi
detect
definit
attribut
infect
vs
colon
possibl
confirm
role
incept
chronic
inflammatori
process
prospect
random
studi
best
therapeut
intervent
perform
modern
multiplex
pcr
approach
detect
extend
spectrum
pathogen
parallel
therebi
reduc
cost
materi
personnel
although
approach
intrigu
realiti
check
publish
method
often
yield
much
lower
detect
rate
expect
problem
probabl
overcom
recent
upgrad
multiplex
assay
describ
khanna
et
al
author
develop
assay
combin
multiplex
pcr
hybrid
assay
highli
specif
highli
sensit
almost
year
first
descript
rsv
physician
attend
children
viral
respiratori
tract
diseas
asthma
still
await
develop
effect
econom
inexpens
medic
prevent
treatment
respiratori
viral
infect
infant
major
respiratori
virus
specif
therapi
avail
imped
infect
inhibit
viral
replic
infect
host
case
treatment
symptomat
specif
intervent
fight
pathogen
contrast
bronchiol
hospit
infant
children
without
histori
asthma
recurr
wheez
earli
administr
system
corticosteroid
repres
primari
mean
treatment
sever
asthma
exacerb
irrespect
acut
infect
except
varicella
zoster
viru
infect
system
corticosteroid
given
system
aciclovir
coverag
neuraminidas
inhibitor
oseltamivir
zanamivir
activ
influenza
virus
avail
treatment
microbiolog
confirm
influenza
substanc
inhibit
enzymat
activ
neuraminidas
thought
prevent
releas
newli
bud
progeni
virion
cell
surfac
neuraminidas
inhibitor
use
earli
within
first
hour
cours
diseas
even
chemoprophylaxi
thu
rapid
laboratori
diagnost
test
detect
viral
rna
viral
antigen
mandatori
guid
decis
treatment
anoth
possibl
prevent
influenzatrigg
asthma
prevent
infect
vaccin
although
possibl
highli
desir
major
disadvantag
vaccin
target
actual
influenza
strain
epidem
season
new
strain
emerg
recent
observ
avian
influenza
viru
new
specif
vaccin
must
develop
gener
avail
middl
ongo
epidem
next
epidem
season
howev
strongli
recommend
vaccin
highrisk
group
especi
increas
risk
asthma
near
futur
newer
vaccin
formul
live
attenu
influenza
vaccin
strain
may
complement
current
vaccin
strategi
specif
passiv
immunoprophylaxi
also
nonspecif
antivir
therapi
avail
prevent
treat
infect
human
rsv
first
option
immunoprophylaxi
palivizumab
human
monoclon
antibodi
bind
highli
conserv
f
protein
rsva
rsvb
subtyp
efficaci
palivizumab
mainli
signific
reduct
percentag
children
rehospit
rsv
infect
first
month
life
test
two
welldesign
prospect
random
doubleblind
multicent
studi
howev
prophylact
use
antibodi
limit
due
high
cost
thu
applic
recommend
highrisk
prematur
infant
infant
hemodynam
relev
congenit
heart
diseas
level
evid
rsvinfect
patient
allogen
blood
stem
cell
transplant
antivir
therapi
rsv
infect
possibl
sometim
success
ribavirin
administ
inhal
aerosol
smallparticl
aerosol
gener
therapi
may
option
case
lifethreaten
rsv
infect
mechan
ventil
prematur
infant
sever
immunocompromis
children
latter
group
ribavirin
suggest
treatment
option
patient
sever
influenza
parainfluenza
viru
infect
even
highrisk
popul
routin
use
controversi
due
lack
evid
signific
benefit
random
control
studi
well
cost
issu
potenti
toxic
teratogen
patient
expos
caregiv
one
studi
ribavirin
use
infant
sever
bronchiol
observ
longterm
benefit
subsequ
airway
hyperreag
even
could
confirm
control
trial
valid
clinic
laboratori
paramet
indic
subgroup
patient
experi
posit
outcomea
review
weinberg
number
compound
known
display
margin
cytotox
effect
highli
activ
rsv
inocul
tissu
cultur
three
compound
alreadi
test
phase
phase
ii
trial
pleconaril
rsv
rf
howev
neither
ribavirin
new
therapeut
agent
activ
rsv
assess
licens
use
children
recurr
wheez
asthma
respiratori
virus
frequent
detect
schoolag
children
asthma
rhinovirus
specif
treatment
rhinovirus
avail
yet
increas
number
promis
drug
candid
develop
even
earli
phase
clinic
trial
one
drug
success
pass
phase
ii
clinic
trial
rupintrivir
select
irrevers
inhibitor
rhinovir
administ
intranas
peptidomimet
compound
poor
aqueou
solubl
low
oral
bioavail
anim
well
toler
healthi
adult
volunt
pleconaril
may
anoth
futur
option
treatment
rhinoviru
infect
inhibit
attach
viru
host
cell
receptor
uncoat
viral
nucleic
acid
pleconaril
appli
oral
distribut
upper
lower
airway
enter
absorpt
infect
rhinovirus
howev
major
inclus
criterion
clinic
studi
pleconaril
import
cellular
receptor
attach
rhinovirus
experiment
approach
inhibit
virusreceptor
interact
monoclon
antibodi
antagonist
molecul
one
antibodylik
compound
cfi
recombin
antibodi
fusion
protein
may
promis
candid
investig
clinic
trial
anoth
compound
tremacamra
consist
deriv
transmembran
intracellular
domain
truncat
specif
therapi
vaccin
lack
human
metapneumoviru
respiratori
coronavirus
furthermor
data
experiment
usag
antivir
vitro
inhibit
replic
virus
ambival
promis
even
develop
specif
vaccin
yet
success
expect
human
metapneumoviru
untreat
viral
pathogen
prospect
control
studi
need
confirm
refut
efficaci
therapeut
intervent
infant
children
recurr
wheez
asthma
bronchiol
pneumonia
proven
prospect
random
doubleblind
studi
suffici
power
certain
therapeut
intervent
posit
impact
ill
sever
breath
rate
oxygen
satur
length
inpati
care
necess
admit
patient
intens
care
unit
start
mechan
ventil
also
import
identifi
evidencebas
treatment
method
avoid
unjustifi
consumpt
financi
resourc
context
system
treatment
corticosteroid
inhal
treatment
beta
mimet
adrenalin
epinephrin
investig
critic
exampl
epidemiolog
studi
publish
till
hmpvinfect
hospit
pediatr
patient
receiv
system
corticosteroid
half
treat
bronchodil
due
increas
number
clinic
relev
viral
respiratori
pathogen
also
increas
number
newli
develop
antivir
drug
absolut
prerequisit
specif
treatment
remain
rapid
specif
diagnost
approach
specif
therapi
option
viral
infect
summar
tabl
treatment
erythromycin
lesser
still
consider
extent
clarithromycin
may
result
clinic
relev
potenti
toxic
interact
drug
two
macrolid
metabol
via
hepat
cytochrom
microsom
enzym
relev
patient
asthma
profound
elev
theophyllin
plasma
level
enhanc
cardiotox
antihistamin
like
terfenadin
prolong
qt
interv
increas
risk
ventricular
arrhythmia
torsad
de
point
azithromycin
interact
enzym
may
combin
without
subsequ
problem
eg
exampl
cyclosporin
stem
cell
organ
transplant
control
trial
avail
optim
durat
treatment
childhood
atyp
bacteri
tracheobronch
pneumonia
consid
observ
persist
colon
convent
treatment
regimen
particular
c
pneumonia
infect
seem
reason
use
prolong
treatment
schedul
children
asthma
confirm
atyp
bacteria
infect
suggest
esposito
et
al
azithromycin
ie
mgkgday
day
per
week
consecut
week
altern
use
clarithromycin
least
day
may
consid
well
design
random
control
trial
clearli
need
examin
effect
differ
antibiot
pneumonia
c
pneumonia
optim
dose
durat
therapi
variou
patient
popul
although
number
pathogen
suspect
associ
acut
chronic
asthma
pathogenesi
childhood
increas
number
option
specif
therapi
avail
near
futur
also
increas
thu
start
therapi
strongli
recommend
clinician
perform
rapid
clinic
laboratori
diagnosi
accompani
detail
histori
thereaft
specif
individu
therapi
regimen
consid
order
avoid
develop
resist
minim
drugspecif
advers
effect
unnecessari
drug
interact
manner
treatment
may
avoid
acut
andor
chronic
asthma
affect
patient
